Iván Martínez-Baz

Profesor asociado

Universidad de Navarra

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Epidemiology

100%

Virology

100%

Covid-19

80%

Pandemic Preparedness

70%

Influenza Research

60%

Sars-cov-2

60%

Public Health

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Article Link

Year:

2024

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Article Link

Year:

2024

Prevalence of Respiratory Viral Infections in Deceased Persons during the COVID-19 Pandemic Season 2021–2022: A Population-Based Observational Study

Article Link

Year:

2024

Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study

Article Link

Year:

2024

Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.

Article Link

Year:

2024

Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023

Article Link

Year:

2023

Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study

Article Link

Year:

2023

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study

Article Link

Year:

2023

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.

Article Link

Year:

2023

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Article Link

Year:

2023

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Article Link

Year:

2023

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Article Link

Year:

2023

Assessment of Knowledge and Attitudes Over Time in Postacute COVID-19 Environments: Protocol for an Epidemiological Study

Article Link

Year:

2023

[Morbi-mortality of lower respiratory tract infections and vaccination].

Article Link

Year:

2023

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.

Article Link

Year:

2022

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.

Article Link

Year:

2022

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.

Article Link

Year:

2022

Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22.

Article Link

Year:

2022

Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.

Article Link

Year:

2022

Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases.

Article Link

Year:

2022

Collaborators10

Heather Whitaker

Open University

UNITED KINGDOM

Irina Kislaya

Bernhard Nocht Institute for Tropical Medicine

GERMANY

Maria Eugenia Portillo

SPAIN

Pere Godoy

SPAIN

Clara Mazagatos

Instituto de Salud Carlos III

SPAIN

Itziar Casado

Instituto de Salud Pública de Navarra

SPAIN

Jesus Castilla

Instituto de Salud Pública de Navarra

SPAIN

Caroline GUERRISI

FRANCE

Patricia Soares

PORTUGAL

Hinta Meijerink

Norwegian Institute of Public Health

NORWAY

How do I reach out?

Meet Kite AI

Iván Martínez-Baz

Profesor asociado

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles20

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Prevalence of Respiratory Viral Infections in Deceased Persons during the COVID-19 Pandemic Season 2021–2022: A Population-Based Observational Study

Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study

Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.

Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023

Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I-MOVE primary care multicentre study

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Assessment of Knowledge and Attitudes Over Time in Postacute COVID-19 Environments: Protocol for an Epidemiological Study

[Morbi-mortality of lower respiratory tract infections and vaccination].

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.

Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22.

Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.

Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases.

Collaborators10

Heather Whitaker

Irina Kislaya

Maria Eugenia Portillo

Pere Godoy

Clara Mazagatos

Itziar Casado

Jesus Castilla

Caroline GUERRISI

Patricia Soares

Hinta Meijerink

How do I reach out?

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.